Nurix Therapeutics
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical enterprise headquartered in San Francisco, California. The company focuses on the discovery, development, and commercialization of small molecule immunomodulatory drugs targeting protein degradation pathways for the treatment of cancer and inflammatory diseases. Its proprietary DELigase platform utilizes targeted protein degradation technology to address challenging therapeutic targets. Principal revenue is currently earned through pharmaceutical research collaboration agreements, clinical milestone payments, and licensing royalties. Nurix Therapeutics Inc is publicly listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Nurix Therapeutics.
- Legal name
- Nurix Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Nurix Therapeutics
- Handelsbanken Helse Tema — Handelsbanken · 0.73 % (full portfolio disclosed, October 2026)
- Swedbank Robur Healthcare — Swedbank · 0.15 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)